Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis
- 1 July 2005
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 164 (1-2) , 10-21
- https://doi.org/10.1016/j.jneuroim.2005.02.022
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matterPhysiological Genomics, 2004
- A Role for Caspase-1 and -3 in the Pathology of Experimental Allergic EncephalomyelitisThe American Journal of Pathology, 2002
- Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell deathThe Journal of cell biology, 2002
- Treatment of spinal muscular atrophy by sodium butyrateProceedings of the National Academy of Sciences, 2001
- Regulation of Neuronal Traits by a Novel Transcriptional ComplexNeuron, 2001
- Oxidative stress and S‐nitrosylation of proteins in cellsBritish Journal of Pharmacology, 2000
- Differential Expression of Human Histone Deacetylase mRNAs in Response to Immune Cell Apoptosis Induction by Trichostatin A and ButyrateBiochemical and Biophysical Research Communications, 1998
- Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune CellsBiochemical and Biophysical Research Communications, 1998
- Phosphatidylinositol 3-Kinase Couples the Interleukin-2 Receptor to the Cell Cycle Regulator E2FImmunity, 1997
- Expression of Neuronal Traits in Pancreatic Beta CellsPublished by Elsevier ,1997